Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from COSCIENS Biopharma ( (TSE:CSCI) ).
On March 25, 2026, COSCIENS Biopharma reported fourth-quarter and full-year 2025 results, highlighting a sharp reduction in losses driven by a major restructuring following a board reconstitution in May 2025. The company cut R&D, impairment and SG&A expenses, ending 2025 with $7.3 million in cash, a narrowed annual net loss of $10.4 million versus $15.3 million in 2024, and lower revenue of $7.5 million, mainly due to reduced pharmaceutical and active-ingredient sales.
The company is exiting its Biopharmaceutical Business by ceasing funding to its German subsidiaries, which led to an insolvency application filed on March 23, 2026, and is expected to generate about $1.9 million in annualized savings and remove roughly $11.0 million of pension-related liabilities from its balance sheet. COSCIENS also plans to further trim costs by ending or suspending its U.S. Exchange Act reporting while maintaining Canadian reporting status and TSX and OTC listings, as management focuses on achieving profitability and pursuing value-enhancing strategic options in 2026.
More about COSCIENS Biopharma
COSCIENS Biopharma Inc. is a life sciences company focused on developing natural, plant-based active ingredients, leveraging proprietary manufacturing and extraction technologies. Its key products include avenanthramides and beta glucan ingredients, which are supplied to leading skincare brands globally, with its shares listed on the TSX and traded on the OTCQB market.
Average Trading Volume: 2,480
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$4.2M
See more data about CSCI stock on TipRanks’ Stock Analysis page.